Skip to main navigation Skip to main content
info(at)avldigital.remove-this.de
Deutsch English
Last searches

Results for *

Displaying results 1 to 3 of 3.

  1. Accelerating Vaccine Innovation for Emerging Infectious Diseases via Parallel Discovery
    Author: Barberio, Joseph; Becraft, Jacob; Ben Chaouch, Zied; Bertsimas, Dimitris; Kitada, Tasuku; Li, Michael Lingzhi; Lo, Andrew W.; Shi, Kevin; Xu, Qingyang
    Published: [2023]
    Publisher:  SSRN, [S.l.]

    The portfolio approach of financing drug development has been proposed as a financial innovation to improve the risk/return tradeoff of investment in drug development projects through the use of diversification and securitization. By investing in a... more

    Access:
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan

     

    The portfolio approach of financing drug development has been proposed as a financial innovation to improve the risk/return tradeoff of investment in drug development projects through the use of diversification and securitization. By investing in a sizable and well-diversified portfolio of novel drug candidates, and issuing equity and securitized debt based on this portfolio, the financial performance of such a biomedical “megafund” can be made attractive to a wide group of investors in the private sector. To analyze the viability of the portfolio approach in expediting vaccine development against emerging infectious diseases, we simulate the financial performance of a hypothetical vaccine megafund consisting of 120 mRNA vaccine candidates in the preclinical stage, which target 11 emerging infectious diseases, including a hypothetical “disease X,” which may cause the next global pandemic. We calibrate the simulation parameters with input from domain experts in mRNA technology and an extensive literature review. We find that this vaccine portfolio will generate an average annualized return on investment of −6.0% per annum and a negative net present value of −$9.5 billion, despite the scientific advantages of mRNA technology and the financial benefits of diversification. We also show that clinical trial costs account for 94% of the total investment, while vaccine manufacturing costs account for only 6%. The most important factor of the megafund's financial performance is the price per vaccine dose, while other factors, such as the increased probability of success due to mRNA technology, the size of the megafund portfolio, and the possibility of conducting human challenge trials do not significantly improve its financial performance. Our results illustrate the critical importance of government funding to ensure that vaccine development will be financially sustainable for the private sector and that effective vaccines will be available to prevent the next global pandemic

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Other identifier:
    Series: MIT Sloan Research Paper ; No. 6858-23
    Subjects: Vaccines; mRNA; Megafund; Pandemics; Epidemics; Infectious Diseases; Healthcare Finance
    Other subjects: Array
    Scope: 1 Online-Ressource (31 p)
    Notes:

    Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments March 16, 2023 erstellt
  2. Innovation and patenting activities of COVID-19 vaccines in WTO members
    analytical review of Medicines Patent Pool (MPP) COVID-19 Vaccines Patent Landscape (VaxPaL)
    Author: Chiang, Ting-Wei; Wu, Xiaoping
    Published: 10 February 2022
    Publisher:  World Trade Organization, Economic Research and Statistics Division, [Geneva]

    This working paper provides a statistical analysis of 74 patent families which cover subject matter relevant to ten COVID-19 vaccines. These vaccines have accounted for 99% of the global COVID-19 vaccine production as of 31 December 2021, comprising... more

    Access:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    DS 122
    Inter-library loan:
    No inter-library loan

     

    This working paper provides a statistical analysis of 74 patent families which cover subject matter relevant to ten COVID-19 vaccines. These vaccines have accounted for 99% of the global COVID-19 vaccine production as of 31 December 2021, comprising over ten billion doses. Eight of them, namely BNT162b2 (Pfizer/BioNTech), AZD1222 (AstraZeneca/Oxford), Ad26.COV2-S (J&J), mRNA1273 (Moderna), BBIBP-CorV (Sinopharm/Beijing), Coronavac (Sinovac), Covaxin (Bharat/ICMR), and NVX-CoV2373 (Novavax), have been approved by the World Health Organization (WHO) for inclusion in its Emergency Use Listing (EUL). The analysis is based on VaxPaL, a COVID-19 vaccines patent database developed by the Medicines Patent Pool (MPP). Through the detailed examination of patent applicants, filing dates, and offices of first and subsequent filing, the paper identifies patterns and trends of innovation and patenting activities of COVID-19 vaccines in WTO Members, and presents the legal status of the 74 patent families in 105 jurisdictions. This information may provide useful background for policymakers on the significance and potential impact of these patent families with relevance to the access to and production of these vaccines in their individual countries. This, in turn, may help support practical assessments as to potential options within and beyond the current TRIPS framework to promote equitable access to COVID-19 vaccines.

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Other identifier:
    hdl: 10419/250745
    Edition: Manuscript date: 18 January 2022
    Series: Staff working paper ; ERSD-2022, 01
    Subjects: COVID-19; vaccine; patent; whole virus; viral vector; protein subunit; mRNA; filing dates; office of first filing; office of subsequent filing; legal status
    Scope: 1 Online-Ressource (circa 41 Seiten), Illustrationen
  3. Accelerating Vaccine Innovation for Emerging Infectious Diseases via Parallel Discovery
    Author: Barberio, Joseph; Becraft, Jacob; Ben Chaouch, Zied; Bertsimas, Dimitris; Kitada, Tasuku; Li, Michael Lingzhi; Lo, Andrew W.; Shi, Kevin; Xu, Qingyang
    Published: June 2022
    Publisher:  National Bureau of Economic Research, Cambridge, Mass

    We analyze the financial performance of a hypothetical portfolio of 120 mRNA vaccine candidates in the preclinical stage targeting 11 emerging infectious diseases. We calibrate the simulation parameters with input from domain experts in mRNA... more

    Access:
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Sächsische Landesbibliothek - Staats- und Universitätsbibliothek Dresden
    Inter-library loan:
    No inter-library loan

    Location:
    Universitätsbibliothek Freiburg
    Inter-library loan:
    No inter-library loan

    Location:
    Helmut-Schmidt-Universität, Universität der Bundeswehr Hamburg, Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
    Inter-library loan:
    No inter-library loan

    Location:
    Technische Informationsbibliothek (TIB) / Leibniz-Informationszentrum Technik und Naturwissenschaften und Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan

     

    We analyze the financial performance of a hypothetical portfolio of 120 mRNA vaccine candidates in the preclinical stage targeting 11 emerging infectious diseases. We calibrate the simulation parameters with input from domain experts in mRNA technology and an extensive literature review. We find that the portfolio generates an average annualized return on investment of -6.0% per annum and a net present value of -$9.5 billion, despite the scientific advantages of mRNA technology and the financial benefits of diversification. Clinical trial costs account for 94% of the total investment, with manufacturing costs accounting for only 6%. Sensitivity analysis reveals that the most important factor determining financial performance is the price per dose, while the increased probability of success due to mRNA technology, adjusting the size of the portfolio, and the possibility of conducting human challenge trials do not significantly improve financial performance. These results underscore that if the goal is to create a sustainable business model and robust global vaccine ecosystem, continued collaboration between government agencies and the private sector is likely to be necessary

     
    Export to reference management software   RIS file
      BibTeX file